ERBB2 and breast carcinoma: Thus, this work aims to compare the combined effect of paclitaxel and a slow sulfide donor GYY4137 as a reducing agent on triple negative MDA-MB-231 cells and HER2-positive JIMT1 breast cancer cells and try to elucidate the mechanism of possible effect observed.